$CTXR

H.C. Wainwright began coverage of Citius Pharmaceuticals (CTXR) on May 18 with a Buy rating and $4 price target, citing LYMPHIR’s approval for relapsed/refractory Stage I-III cutaneous T-cell lymphoma and encouraging early launch metrics. The report notes near-full commercial insurance coverage and initial Europe shipments via a regional partner. CTXR’s U.S. launch began in Dec. 2025.

Citius Pharmaceuticals (NASDAQ:CTXR) held its 2026 annual meeting where shareholders elected seven members to its board of directors for a one-year term. The company's shareholders also ratified Wolf & Company, P.C. as their independent registered public accounting firm for the fiscal year ending September 30, 2026. The information was based on an SEC filing.

Citius Pharmaceuticals reported strong early commercial momentum for LYMPHIR, demonstrating rapid institutional adoption with 83% of target accounts reviewing the product and broad payer coverage secured for approximately 80% of lives. The company is seeing sequential growth in orders and no reported reimbursement denials, while continuing its commercial buildout efforts.

Citius Oncology, a subsidiary of Citius Pharmaceuticals (CTXR), reported positive early commercial progress for LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), estimating an initial market exceeding $400 million. The company highlighted growing formulary adoption in oncology centers, expanding payer coverage, and repeat orders, alongside advancing clinical development through academic collaborations for other lymphoma and solid tumors. Key safety concerns for LYMPHIR include capillary leak syndrome, infusion-related reactions, hepatotoxicity, visual impairment, and embryo-fetal toxicity.

Analysts are predicting that Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) will reach breakeven by 2027, transitioning from a projected loss in 2026 to positive profits of US$78m. This forecast implies an optimistic year-on-year growth rate of 48%. The company's low debt-to-equity ratio of 1.3% is highlighted as a positive financial management indicator.

Citius Pharmaceuticals ( NASDAQ:CTXR ) , a late-stage biopharmaceutical company focused on developing and commercializing critical care therapies, reported its earnings for the fiscal third quarter of 2025 on August 12, 2025.

Citius announces a $15.8 million direct offering. The company plans to use the proceeds to support the commercial launch of LYMPHIR™, as well as for general corporate purposes. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.

Citius announces a distribution services agreement with Cardinal Health. Cardinal serves as an authorized distributor of record for Citius Oncology, providing specialty pharmaceutical distribution services. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Ashley Owens downgraded the rating for Deckers Outdoor Corporation DECK from ...